Millendo Therapeutics Announces Pricing of Public Offering of Common Stock

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announced the pricing of its underwritten public offering of 4,166,667 shares of its common stock at a public offering price of $6.00 per share, for aggregate gross proceeds of $25.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Millendo. In addition, Millendo has granted the underwriters a 30-day option to purchase up to 625,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares are being sold by Millendo. The offering is expected to close on December 9, 2019, subject to the satisfaction of customary closing conditions.